LAVA Therapeutics (NASDAQ:LVTX) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report sent to investors on Friday morning, Marketbeat.com reports. They currently have a $6.00 price target on the stock.

LAVA Therapeutics Price Performance

Shares of NASDAQ LVTX opened at $1.87 on Friday. LAVA Therapeutics has a 1-year low of $1.13 and a 1-year high of $6.47. The company has a quick ratio of 7.42, a current ratio of 7.42 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $2.50 and a two-hundred day moving average of $2.34.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Tuesday, May 21st. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.23. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%. The company had revenue of $6.99 million during the quarter. On average, equities research analysts expect that LAVA Therapeutics will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC purchased a new position in shares of LAVA Therapeutics (NASDAQ:LVTX) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,000 shares of the company’s stock, valued at approximately $47,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.